Morphic Holding, Inc. (MORF)

NASDAQ: MORF · IEX Real-Time Price · USD
21.80
+0.10 (0.46%)
Jul 1, 2022 1:02 PM EDT - Market open

Company Description

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer.

Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.

The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications.

It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics.

Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Morphic Holding, Inc.
Country United States
Founded 2014
IPO Date Jun 27, 2019
Industry Biotechnology
Sector Health Care
Employees 100

Contact Details

Address:
35 Gatehouse Dr # A2
Waltham, Massachusetts 02451-1215
United States
Phone 781 996 0955
Website morphictx.com

Stock Details

Ticker Symbol MORF
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $15.00
CIK Code 1679363
CUSIP Number 61775R105
ISIN Number US61775R1059
SIC Code 2834

Key Executives

Name Position
Dr. Praveen P. Tipirneni M.D. Chief Executive Officer, MD and Director
Dr. Bruce N. Rogers Ph.D. President
Dr. Timothy A. Springer Ph.D. Founder, Independent Director and Member of Scientific Advisory Board
Dr. Marc Schegerin M.B.A., M.D. Chief Financial Officer and Chief Operating Officer
William D. DeVaul Esq. General Counsel and Secretary
Robert E. Farrell Jr., CPA, CPA Senior Vice President of Finance and Operations and Chief Accounting Officer
Dr. Blaise Lippa Ph.D. Chief Scientific Officer
Aaron Pelta Senior Vice President of Business and Corporate Development
Joanne Gibbons Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Jun 21, 2022 8-K Current report
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 10, 2022 4 Statement of changes in beneficial ownership of securities
Jun 9, 2022 8-K Current report